Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART

[Guest guest]

Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART

http://www.finanznachrichten.de

PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Pharmasset, (Nachrichten)

Inc. announces that interim results of physician-sponsored studies of clevudine

for the treatment of chronic hepatitis B virus (HBV) and both preclinical and

clinical results of R7128 for the treatment of chronic hepatitis C virus (HCV)

will be presented at the Frontiers in Drug Development in Viral Hepatitis

(HEP-DART) conference being held in Lahaina, Hawaii from December 9 - 13, 2007.

The abstract titles and abbreviated study summaries are described below. The

full conference abstracts are currently available for download in PDF format in

the " Events & Presentations " section of Pharmasset's website at

http://investor.pharmasset.com/events.cfm. The full scientific presentations

will be available for download in PDF format following the conference in the

" Product Pipeline " section of Pharmasset's website at

http://www.pharmasset.com/pipeline.

Clevudine was Superior to Lamivudine in the Patients with HBeAg(+) Chronic

Hepatitis B. GK Lau, et al.

Abstract Summary: The aim of this study is to compare the efficacy and safety of

clevudine versus lamivudine for 48 weeks in chronic hepatitis B (CHB) e-antigen

positive (HBeAg(+)) patients in a randomized and blinded manner. Based on the

preliminary results from 22 patients (11 clevudine, 11 lamivudine), 48-weeks of

dosing with clevudine 30mg showed superior viral suppression to lamivudine 100mg

without the emergence of viral breakthrough in HBeAg(+) CHB patients. At week

48, serum HBV DNA levels were below the level of detection (

_________________________________________________________________

The best games are on Xbox 360. Click here for a special offer on an Xbox 360

Console.

http://www.xbox.com/en-US/hardware/wheretobuy/

[Guest guest]

Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART

http://www.finanznachrichten.de

PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ -- Pharmasset, (Nachrichten)

Inc. announces that interim results of physician-sponsored studies of clevudine

for the treatment of chronic hepatitis B virus (HBV) and both preclinical and

clinical results of R7128 for the treatment of chronic hepatitis C virus (HCV)

will be presented at the Frontiers in Drug Development in Viral Hepatitis

(HEP-DART) conference being held in Lahaina, Hawaii from December 9 - 13, 2007.

The abstract titles and abbreviated study summaries are described below. The

full conference abstracts are currently available for download in PDF format in

the " Events & Presentations " section of Pharmasset's website at

http://investor.pharmasset.com/events.cfm. The full scientific presentations

will be available for download in PDF format following the conference in the

" Product Pipeline " section of Pharmasset's website at

http://www.pharmasset.com/pipeline.

Clevudine was Superior to Lamivudine in the Patients with HBeAg(+) Chronic

Hepatitis B. GK Lau, et al.

Abstract Summary: The aim of this study is to compare the efficacy and safety of

clevudine versus lamivudine for 48 weeks in chronic hepatitis B (CHB) e-antigen

positive (HBeAg(+)) patients in a randomized and blinded manner. Based on the

preliminary results from 22 patients (11 clevudine, 11 lamivudine), 48-weeks of

dosing with clevudine 30mg showed superior viral suppression to lamivudine 100mg

without the emergence of viral breakthrough in HBeAg(+) CHB patients. At week

48, serum HBV DNA levels were below the level of detection (

_________________________________________________________________

The best games are on Xbox 360. Click here for a special offer on an Xbox 360

Console.

http://www.xbox.com/en-US/hardware/wheretobuy/